Screener
King Pharmaceuticals KG Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount
Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount.
The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 8:49 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054606
FAQ
- What is King Pharmaceuticals's liability for unpaid claims and claims adjustment expense reported claims amount?
- King Pharmaceuticals (KG) reported liability for unpaid claims and claims adjustment expense reported claims amount of $269.15M in Q2 2026.
- How has King Pharmaceuticals's liability for unpaid claims and claims adjustment expense reported claims amount changed year-over-year?
- King Pharmaceuticals's liability for unpaid claims and claims adjustment expense reported claims amount decreased by 24.0% year-over-year, from $354.14M to $269.15M.
- What does liability for unpaid claims and claims adjustment expense reported claims amount mean?
- Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount as reported by Kestrel Group Ltd.
Ask your AI about King Pharmaceuticals's liability for unpaid claims and claims adjustment expense reported claims amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude